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Introduction
Regular physical exercise is undoubtedly 
beneficial for humans. Since the 1950s, numerous 
prospective follow-up studies have assessed both 
all-cause and cardiovascular (CV) mortality in rela-
tion to levels of physical activity. The results have 
always been unambiguous. Both men and women 
who presented with higher levels of physical ac-
tivity were found to have a reduced risk of death 
(by up to 50%). Noteworthy, those who maintain 
a physically active lifestyle but at the same time 
present with other risk factors for CV diseases 
(CVD; smoking, hyperlipidemia, hypertension, 
diabetes, obesity) appear to be at a lower risk of 
premature death than sedentary subjects without 
risk factors [1]. Physical activity reduces the inci-
dence of hypertension, ischemic heart disease and 
CV events, type 2 diabetes, cancers (in particular 
colon and breast cancer) and osteoporosis [2]. 
Furthermore, when applied in the secondary pre-
vention of CVD, regular physical exercise, regular 
physical exercise reduces all-cause mortality.
Whether for health-related reasons or not, the 
number of people participating in sports activities 
is increasing and healthy lifestyle has indeed be-
come fashionable in the last decade. In addition, 
extreme forms of endurance exercise such as mara-
thon, triathlon and ironman triathlon have become 
increasingly popular among amateurs. Globally, the 
number of marathon runners increased by 13% in 
2009–2014 and 0.5% of the United States popula-
tion participated in at least one marathon [3, 4]. 
Amateur participation in these extreme sports is 
associated with the need for hours of training, often 
daily, and competitions are exhausting. 
Thus, a question arises whether in spite of un-
disputable health benefits connected with physical 
activity, such intensive forms of endurance sport 
still continue to be so, or if they can adversely af-
fect the cardiovascular system. 
Is more always better? 
Sports-related cardiovascular risks
Proarrhythmia
As in the general population, atrial fibrillation 
(AF) is the most common arrhythmia in athletes. 
Multiple studies indicate that the risk of AF in 
athletes is higher compared to non-athletes [5]. It 
is believed that chronic intensive physical training 
predisposes to this arrhythmia mostly due to the 
left atrial enlargement, increased left ventricular 
mass and increased vagal tone [6].
Metabolic changes and adrenergic activation 
caused by intensive exercise are known to trigger 
life-threatening arrhythmias in predisposed hearts, 
or in other words in the presence of structural 
heart disease. In a cohort study performed among 
young subjects in Veneto, Italy, the risk of sudden 
cardiac death among competitive (i.e. regularly 
training and participating in competitions) athletes 
was compared to that in a non-athletic population. 
A 2.5-fold higher risk of sudden cardiac death was 
shown among competitive athletes, and was related 
to structural heart disease including coronary ar-
tery anomalies, arrhythmogenic right ventricular 
(RV) cardiomyopathy or ischemic heart disease [7]. 
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However, even in the absence of structural heart 
disease, a question arises concerning possible 
negative effects of intense physical exercise and 
participation in extreme sports on the CV system.
Hemodynamics and right ventricular  
dysfunction
In a study among Boston marathon amateur 
participants, completion of the marathon was as-
sociated with increased pulmonary artery pressure, 
increased RV dimensions and impaired RV systolic 
function [8]. Imaging techniques reveal RV func-
tional abnormalities immediately after an intensive 
endurance exercise. In the study by La Gerche et 
al. [9] in athletes who completed ultra-triathlon, 
transthoracic echocardiography showed signifi-
cant RV dysfunction, reduced tricuspid annular 
plane systolic excursion (TAPSE) and reduced RV 
fractional area change (RV FAC). In some athletes, 
cardiac magnetic resonance showed delayed con-
trast enhancement (consistent with fibrosis) within 
the right-sided interventricular septum.
Intensive exercise results in a greater increase 
in pulmonary artery pressure relative to systemic 
pressure, as the pulmonary vascular bed is charac-
terized by lower adaptive capacity which does not 
improve under regular training. Thus, the RV which 
generates the same cardiac output as the left ven-
tricle, is subjected to greater afterload which does 
not decrease with repeated training. Compared with 
rest, the RV wall tension in athletes increases by 
170% during exercise, compared to a 23% increase 
in the left ventricular wall tension. This may lead 
to RV hypertrophy and remodeling [10].
In addition to imaging techniques, also bio-
chemical parameters and biomarkers are used 
to determine the effect of intensive endurance 
training on the RV function. A significant increase 
in cardiac troponin and B-type natriuretic peptide 
(BNP) levels observed immediately after exertion, 
indicated myocardial damage and were correlated 
with echocardiographic RV systolic dysfunction [11].
Cardiac remodeling and fibrosis
In an interesting experimental study in rats, 
Benito et al. [12] evaluated the effect of physical 
exercise on myocardial remodeling and its poten-
tial arrhythmogenic effect. Following 16 weeks 
of intensive training, collagen deposits that dis-
rupted tissue architecture were identified in the 
RV myocardial intercellular spaces. Such changes 
were not detected in the left ventricle. In addition, 
programmed RV stimulation induced ventricular 
tachycardia in 42% of rats in the training group 
compared to only 6% in the control group. This 
study suggests a proarrhythmic effect of adverse 
RV remodeling caused by intensive physical ex-
ercise. These observations were confirmed in 
a study by Ector et al. [13] in a group of well-trained 
endurance athletes. In these subjects, arrhythmias 
originating from the RV were commonly observed, 
even when causes other than intensive training 
were excluded, such as cardiomyopathy and is-
chemic heart disease. In addition, the presence of 
arrhythmias was associated with RV dysfunction. 
Reduced ejection fraction, increased end-systolic 
volume and areas of RV hypokinesis were shown 
by cardiac magnetic resonance imaging.
Some authors go a step further and use the 
term “exercise-induced arrhythmogenic RV cardio-
myopathy”, suggesting that repeated, excessively 
intensive exercise with inadequate regeneration 
periods may lead to potentially arrhythmogenic 
structural cardiac remodeling. The thin-walled 
RV is more prone to volume and pressure over-
load generated during intensive and, in particular, 
endurance training, compared to the left ventricle. 
Microdamage to intercellular junctions may be 
responsible for gradual cardiomyocyte apoptosis 
and their replacement with fibrous tissue, leading 
to arrhythmogenic remodeling [14]. By analogy, 
mutations of desmosomal protein genes are im-
plicated in the pathogenesis of arrhythmogenic RV 
cardiomyopathy, resulting in impaired RV myocar-
dial architecture.
Proinflammation
Studies on pathomechanisms of exercise-
-induced myocardial damage suggest a possible role 
of cytokines and inflammatory responses. Post-
exercise neutrophilia is a well-known phenomenon 
[15]. Previous studies indicated a role of proinflam-
matory cytokines in heart failure (endothelin-1, 
tumor necrosis factor-[TNF]-alpha) [16, 17] and in 
the risk of CV adverse events (interleukin [IL]-6, 
TNF-alpha) [18]. Recently, La Gerche et al. [19] 
were the first to show that myocardial dysfunc-
tion secondary to intense endurance exercise (as 
evidenced by elevated cardiac troponin and BNP 
levels along with a reduction in RV ejection frac-
tion) was associated with increased blood levels 
of proinflammatory cytokines including TNF-alpha 
and IL-12p70i. Taking into account known effects of 
these cytokines, it may be suspected that repeated 
intensive physical exercise and associated inflam-
matory reactions may lead to fibrosis. In addition, 
the RV may be more involved as it is exposed to 
significant pressure overload during exercise. 
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Experimental studies show that TNF-alpha plays 
a major role in cardiomyocyte apoptosis along with 
damage and replacement fibrosis in different condi-
tions of cardiac pressure overload [20].
The role of novel biomarkers
Although nowadays imaging techniques are 
crucial for evaluation of structure and function 
of the heart, cardiac biomarkers still remain an 
important field for further research. The standard 
laboratory analysis has remained unchanged in re-
cent years and it involves cardiac troponin I and tro-
ponin T, creatine kinase MB isoenzyme, myoglobin 
and BNP. As already mentioned, exercise-induced 
myocardial damage causes a transient increase in 
concentrations of these markers in serum. In case 
of troponins levels, their concentrations in plasma 
usually normalize within 36 h following the endu-
rance exercise [21].
Recently a number of novel biomarkers have 
been reported. They may play an important role in 
better understanding of the relationship between 
intensive physical exercise and the inflammatory 
response, particularly with regard to the RV func-
tion and proarrhythmia in response to an excessive, 
strenuous exercise. 
Neopterin
Neopterin, a pteridine class compound, is syn-
thesized and released by mononuclear phagocytic 
cells, e.g. macrophages, activated by interferon- 
-gamma or TNF-alpha. The increased neopterin 
level is a marker of activation of cellular inflam-
matory response. Neopterin synthesis is closely 
linked to synthesis of tetrahydrobiopterin, a nitric 
oxide synthase cofactor. Thus, an increased neop-
terin level is observed in conditions with variable 
blood pressure and vascular tone [22]. Already in 
the early 1990s, Sprenger et al. [23] showed an as-
sociation between increased neopterin levels and 
long-distance running. Increased urinary neopterin 
level following extreme exercise is indicative not 
only of cellular inflammatory response, but also of 
increased production of reactive oxygen species 
and reduced antioxidant levels [24].
Experimental studies showed an association 
between AF and increased levels of TNF-alpha 
which contribute to adverse structural atrial re-
modeling, i.e. hypertrophy and fibrosis [25]. Ne-
opterin is a component of TNF-alpha signaling 
pathway and increased neopterin concentrations 
were observed in patients with persistent AF com-
pared to arrhythmia-free subjects [26]. However, 
further studies are needed to establish whether 
neopterin level is a predictor of arrhythmia induced 
by intensive endurance exercise.
Pentraxin-3
Pentraxin-3 (PTX3) is an interesting inflamma-
tory cytokine in the context of studies on adverse 
effects of intensive endurance training on the RV 
function. It is a member of the long pentraxin class, 
contributing to humoral innate immunity along 
with short pentraxins (which include C-reactive 
protein) [27]. PTX3 is believed to play a role in 
atherogenesis, as it is synthesized by macrophages, 
endothelial cells, and vascular smooth muscle cells 
in response to inflammatory signals mediated by 
oxidized low-density lipoproteins [28]. Moreover, 
an association between PTX3 and AF was found. 
PTX3 levels in blood samples obtained from the 
left atrial appendage of subjects suffering from AF 
were significantly higher compared to peripheral 
blood, which may suggest an involvement of local 
inflammatory processes in the pathogenesis of this 
arrhythmia [29]
Nakajima et al. [30] found that compared with 
resting, plasma PTX3 level increased significantly 
immediately after intensive exercise. Circulating 
neutrophils that degranulate in response to exer-
cise were identified as the main source of PTX3. 
In the Multi-Ethnic Study of Atherosclerosis 
(MESA), PTX3 was implicated as a RV function 
marker in subjects without established CVD. The 
elevated PTX3 concentration correlated with 
increased RV mass and end-diastolic volume as-
sessed by cardiac magnetic resonance, and higher 
RV mass was associated with a threefold increase 
in CV or heart failure-related deaths [31].
Galectin-3
Galectin-3, a lectin family protein, is released 
by activated macrophages and its receptors are pre-
sent on cardiac fibroblasts. It is a mediator of fibro-
blast proliferation and thus of collagen production 
and fibrosis initiated by inflammatory reactions. 
Plasma galectin-3 level is increased in patients with 
acute and chronic heart failure, both those with 
reduced (HFrEF) and preserved ejection fraction 
(HFpEF). In both groups of patients, galectin-3 is 
considered a relatively novel biomarker indicating 
poor outcomes [32]. In patients with pulmonary 
arterial hypertension, elevated galectin-3 level 
was found to correlate with echocardiographic RV 
dysfunction and fibrosis, evaluated by levels of 
cardiac extracellular matrix metabolism markers, 
including tissue inhibitor of metalloproteinase 1 
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(TIMP1) and N-terminal propeptide of type III 
procollagen (PIIINP) [33].
Suppression of tumorigenicity 2
The ST2 protein (suppression of tumori-
genicity 2) belongs to the IL-1 receptor family. Its 
ligand is IL-33, shown in animal models to inhibit 
myocardial fibrosis and hypertrophy in response 
to pressure overload. Thus, it has been suggested 
that IL-33 may exert cardioprotective effects in 
various CV conditions [34]. ST2 protein is pre-
sent in two forms: transmembrane (ST2L) and 
soluble (sST2). It was shown that binding of IL-33 
to ST2L counteracts cardiac remodeling induced 
by and catecholamines. The soluble form (sST2), 
being a decoy receptor, binds IL-33 and reduces 
its cardioprotective effects. It is released by car-
diomyocytes and fibroblasts in response to their 
increased tension. In patients with both acute and 
chronic heart failure, sST2 plasma level was shown 
to be a predictor of mortality independently of left 
ventricular ejection fraction. In addition, sST2 may 
be useful to predict the risk of sudden cardiac death 
in relation to left ventricular ejection fraction [35, 
36]. An association was also shown between plasma 
sST2 concentration and echocardiographic param-
eters of RV dysfunction in patients with pulmonary 
hypertension secondary to chronic obstructive 
pulmonary disease [37]. What is important, as 
sST2 antagonizes beneficial effects of IL-33 on 
extracellular matrix remodeling, an increased sST2 
plasma concentration may worsen the conduction 
of electrical impulses in myocardium and thus 
predispose to the occurrence of life-threatening 
arrhythmias, like ventricular tachycardia or ven-
tricular fibrillation [38]. 
Heart-type fatty acid binding protein
Heart-type fatty acid binding protein 
(H-FABP), present in large amounts in the cardio-
myocyte cytosol, is involved in fatty acid metabo-
lism. Even mild cardiomyocyte damage results in 
H-FABP release into the bloodstream and thus, 
a very sensitive and specific marker of acute myo-
cardial ischemia. It was shown to predict mortal-
ity during one-year observation after myocardial 
infarction [39, 40]. High H-FABP levels were also 
shown to predict mortality due to acute right heart 
failure in patients with pulmonary emobolism [41]. 
H-FABP measurements may also be useful as 
a sensitive and specific marker of poor outcomes 
in patients with chronic thromboembolic pulmo-
nary hypertension, including those with previous 
pulmonary endarterectomy [42].
Although examined in terms of RV dysfunc-
tion, neither galectin-3, ST-2, nor H-FABP concen-
trations been studied in healthy subjects involved 
in intensive sports activities and particularly 
endurance exercise. 
Conclusions
In summary, questions whether more inten-
sive physical exercise is better for the CV system 
and whether thresholds exist, and above all, which 
sports activities may not be beneficial, remain 
unanswered. However, this issue becomes more 
urgent due to the mass popularity of sports activi-
ties and increasing engagement in extreme forms 
of endurance exercise. In addition to a multitude 
of evidence supporting the beneficial effects of 
exercise, studies also indicate a threat connected 
with intensive physical exercise, those being the 
dysfunction of RV function, fibrosis, disarray in myo - 
cardial muscle’s architecture and proarrhythmic 
potential. Although the exact pathomechanisms of 
these phenomena have not been fully investigated 
yet, emphasis is put on inflammatory response to 
excessive physical exercise. PTX-3, galectin-3, 
ST-2 and H-FABP have already been linked with RV 
function impairment. Neopterine and PTX-3 have 
been associated with atrial fibrillation, whereas 
ST-2 — is associated with ventricular arrhythmia. 
Further studies are required but the hypothesis of 
a pathological inflammatory response to excessive 
physical exercise appears particularly compelling. 
The use of novel biomarkers could give further 
insight into these processes. 
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